Overview of Current FGFR Inhibitors

Description: This presentation will provide disease/indication, pathophysiology, treatment options and pertinent drug information (efficacy and safety) review for the participant. Patient management and supportive care recommendations will also be highlighted throughout the presentation.

Speaker: Erin Sypolt, PharmD, BCOP, Florida Cancer Specialists and Research Institute

Unprecedented and Unexpected: Dostarlimab in Early Stage Rectal Cancer

Description: Immune checkpoint inhibitors (ICI) have produced impressive results in metastatic colorectal cancer patients with high micro-satellite instability (MSI-H) or deficient DNA mismatch repair (dMMR). Recently, a single institution study presented at the annual ASCO meeting showed very promising response rates with the ICI dostarlimab in early stage rectal cancer patients with MSI-H/dMMR. This activity will educate learners on the current treatment of early stage rectal cancer patients and review the activity of dostarlimab in those with MSI-H/dMMR tumors.

Speaker: Courtney Cavalieri, PharmD, BCOP, Huntsman Cancer Institute